POGIC
We strive day in and day out to become one of the top tier producing Marijuana companies both in Europe and in the US.
Bottom line
This is a turn-key project. We list at the market, You are rewarded.
Logistics
We purchase cannabis from existing farms and re-sell to our pharmaceutical customers.
what makes us different
Who we are ?
what makes us REALLY different
About us
POT OF GOLD IN CORPORATION is a five-year-old company originating in Europe. Our company is a registered entity since 2018 in Ireland bringing tax benefits to all investors. Since the laws have opened up in the United States legalizing Marijuana in certain states per medical use and recreation use we have begun sales in the US since 2022.
We provide cultivators with a clear path forward and help them succeed in the compliant, cannabis industry.
We offer membership packages to cultivators to help lower the overhead costs of operating in the cannabis market.
Our structure allows us to open bank accounts for our members and legally work within the current federal and state confines of the industry.
We will open “Shop Store Locations” in States where it is legal and will continue to open additional shops in additional states where it becomes legal. The stores will be called Pot Of Gold. This will bring added value to all shareholders.
what makes us different
Why would I Invest ?
It’s a turnkey opportunity. We only require 500 shareholders to be able to list on the Nasdaq Index. We list you profit. Your exit strategy within 6 months. The More Act was approved by the House of Representatives last April 2022. This bill removes cannabis from the list of scheduled substances allowing cannabinoid medical product manufactures in America. Pfizer (PFE) has invested since May 2022, $6.7 billion dollars in the buy out of Arena Pharmaceuticals (ARNA) company that holds one specific pipeline dedicated to cannabinoid-type therapeutics. Sleep disorder and chronic pain treatments are now available as an analgesic under the generic name (DRONABINOL) situating us on mainstream sales within the top three Pfizer production pipelines such as Internal Medicine, Oncology and Consumer Healthcare.
Stock Purchase Agreement
Navigating Success with Strategic Stock Allocation.
The Private Placement Subscription Agreement provides the specifics regarding your common stock.
what makes us different
Investment strategy
Own our shares at $2 each. Our company has inherited from our European branch the contingent contracts to sell cannabis to the Pharmaceutical Industry in America, we are the only ones on the block! This creates a perfect situation for our stock to rise in value through your 6- month run at the market as a short-term investment opportunity. Bottom Line we get to list at the market, you profit. It’s a turn-key opportunity.
Stock Purchase Agreement
Profit as soon as we list on the Nasdaq Market
Once listed on the market, the company starts performing at an Initial Valuation Bid from
- ($5.00) a share upon financial requirement criteria or
- ($10) dollars a share upon compelling evidence criteria.
what makes us different
About the shares
Company Shares must be sold as (common stock) at the Nasdaq Market before the shareholder can experience a profit.
Money in money out , for every ($10 ) ten dollars the stock price increases at the market, 100k is your return per every (10000 shares).
If you do the math :
- Pfizer (PFE) doubled the value of ( ARNA ) a recently delisted Nasdaq Company
from ($52) to ($100) a share by investing $6.7 Billion since May (2022) - (ARNA) KEPT ($100) STOCK VALUE FOR 48 WEEKS CONSECUTIVELY BEFORE
DELISTING AS A WHOLLY-OWNED SUBSIDIARY OF PFIZER. - Our main asset, CONTINGENT CONTRACTS WITH THE PHARMACEUTICAL INDUSTRY.
any questions ?
Contact Us
We will send you our PPM upon request and any other information for you the investor to see if we are a good fit for your portfolio.